7 June 2010, Excel Center, Docklands, London, England. J Dumanov and Dr. Michael Rudenko, EAACI London review the origins and effects of non-ionizing and ionizing electromagnetic fields (EMF) and their the resulting clinical indicators of human exposure to be reviewed upon completion. Including ionizing gamma radiation and non-ionizing EMF EMR RF and their potential neurological, physiological and genomic effects on cells, tissue and DNA replication. Clincal case patient exposure (see update 2019) to EMF with multiple sclerosis and the cancers for the integrated diagnosis. BACKGROUND
Professor Dumanov reviewing the development of the protocol of subClinical™ Investigations sC -Ve (electraEMF). With a career spanning over 40 years in EMF EMR related electronics engineering technology and as specialist in EMR RF technology to human clinical molecular biology including the DNA genomic electrophoresis lab has identified many unrecognized sources for the generation of electromagnetic fields (EMF) and being with differing clinical and extremely high risk potential that is currently unknown and unrecognized to be the cause of health disorders that is yet to be published. The studies included LF (common low frequency) 50- 60 Hz consumer electrical service, through the full RF spectrum including microwave cellular and Internet communication systems as integrated, delineated and reviewed by Ching Wu, PhD (Bell, Lucent, AT&T and DOD Labs) the lead communications scientist for the development of 2-3-4 G communications. More recently were included those magnetic fields associated with gamma radiation. Gamma radiation consisting of quanta are presented in the shortest wavelengths with highest energy of any waves such as common short duration x-rays and chronic exposure to uranium and related radon throughout the eastern U.S. Studies and findings identified in the electromagnetic spectrum as observed by scientists in the subClinical EMF Research Lab to be reported for research publication. In 2008 integrated EMF research studies reviewed with Dr. Michael Rudenko, MD (London Allergy Immunology Centre) and Prof. Dr. Aristides Tsatsakis, (Heraklion Medical School Dept. of Forensic Toxicology) non-ionizing and ionizing radiation for clinical environmental studies, subClinical sC - V e ™ protocol for assessing the presence of non-ionizing EMF radiation were conducted amongst the northeastern USA Appalachian Mountain ranges within the states of New Jersey, New York, and Pennsylvania. The presence and levels of LF electromagnetic fields (EMF) were identified along with EMR generating ionizing gamma radiation employing licensed sC-V protocol by EMF testing experts. FINDINGS EMF magnetic fields of flux density from 60 Hz in city/urban areas such as New York City were commonly identified and rural/suburban (Sullivan, Orange, Rockland, Dutchess and Westchester Counties, NY and Bergen, Morris, Essex, Sussex, Rockland and Sussex Counties, NJ). For gamma radiation urban areas of New York City has been identified. In controlled experiments binary exposure to both sources and resulting effecting cell and observed to play a significant role in immune disorders. CONCLUSION We have in mammalian molecular toxicology, allergology and immunology recognized the fields associated within EMF spectrum effecting cells and tissue including causing genetic mutations in DNA as such are amplified when in the presence of both EMF from low to the highest frequency of the ionizing EMF generating spectrum. Often effected patients are those with the cancers, dysthymia(persistent depression), epilepsy, Lyme or multiple sclerosis (MS). The diagnostics require highly advanced human clinical biological integrations and electronic technical surveys employing the sC - V ™ protocol by fully licensed electronic engineers for the presence at risk levels of EMF for identifying the effects for safety, individual health and clinical purposes including other sources not commonly recognized as generating EMF. EMF health risk exposure assessment is highly complex and must be fully understood medically when investigating for the clinical diagnostic. 973-726-9559 NJ NY PA CT DE 347-491-9867 subClinical Environment In the News© 1999-2010(CEIN) |